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. This is an open access article under1. Introduction
Selective serotonin reuptake inhibitors (SSRIs) are amongst the
most prescribed drugs worldwide [1]. Indications for these drugs are
broad and comprise major depression, panic disorder, obsessive–the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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obesity, eating disorders, post-traumatic stress disorder, social phobia
and premenstrual disorder [2]. In comparison to other types of antide-
pressants, SSRIs have a more beneﬁcial adverse effect proﬁle with nau-
sea, diarrhea, sexual dysfunction, headache, dizziness, agitation,
insomnia and under certain circumstances increased suicide risk [2,3].
In addition to these well described side effects, there are indications
from animal studies [4], in vitro studies [5], and some clinical
observations in patients with depression [6] that SSRI treatment may
affect the cellular immune response.
Abnormalities in the proliferation, cytokine secretion and viability of
peripheral blood lymphocytes have been observed when these cells
were exposed to SSRIs. Moreover, the replication and viability of cancer
cells are also affected by SSRIs. Several groups have attempted to reveal
the underlying mechanism by which these effects are executed. An
overview of the immunological effects of SSRIs on immune cells is
provided, both in in vitro and in vivo situations, and special attention is
paid to the role of serotonin (5HT) and its transporter in this effect.
The majority of research reports immunosuppressive effects
of SSRIs such as decreased lymphocyte proliferation and reduced pro-
inﬂammatory cytokine secretion [5,7]. Therefore, SSRIs have already
been tested in several animal models of autoimmune disorders and
graft-versus-host disease [8–14]. However, forﬂuoxetine an immunosup-
pressive as well as an immunostimulatory effect was described,
depending on the concentration used and the degree of lymphocyte
activation in vitro [15,16]. Similarly, the beneﬁcial effect of ﬂuoxetine in
the treatment of lymphoma [17,18] was attributed to both a direct sup-
pressive effect on the malignant cells and a stimulatory effect on anti-
cancer immunity. Thus, it appears that under speciﬁc in vitro and in vivo
conditions, ﬂuoxetine can exert immunostimulatory effects, which seem
applicable in the treatment of lymphoma. The potential applications of
SSRIs in cancer were recently reviewed by Frick and Rapanelli [19]. As
the doses of ﬂuoxetine used in animal models of lymphoma and autoim-
mune disorderswere in the same range (10–25 mg/kg) [11,12,18,20], the
difference between immunostimulation and immunosuppression in vivo
does not rely on the different dose used. Instead, the investigated disease
and its underlying immunological mechanism appear to determine
whether ﬂuoxetine exerts either a stimulatory or a suppressive effect.
For other SSRIs such as paroxetine and sertraline, only immunosuppres-
sive effects have been described [5,8,13]. In this review we will focus on
the immunosuppressive effect of SSRIs.
Based on the observed immunosuppressive effects, the application
of SSRIs in autoimmune disorders and graft-versus-host disease was
examined. Although several research groups have shown improvement
in clinical scores in animal models of autoimmune diseases, discussion
remains about the feasibility of using SSRIs as immunosuppressants in
men, as the doses applied in animal studies are generally higher than
the ones currently used in humans for the treatment of depression.
Nevertheless, limited clinical evidence is available demonstrating the
usefulness of SSRIs in autoimmune disorders.
2. Effects of SSRIs on immune cell functioning
SSRIs have been shown to alter several aspects of immune cell
functioning. Not only the proliferation, but also cytokine secretion and
viability of lymphocytes are affected when exposed to SSRIs. In addition
to lymphocytes, cancer cells also seem to undergo changes when they
are incubated with SSRIs [21–23]. Finally, recent evidence showed
an effect of ﬂuoxetine on neutrophil adhesion and recruitment to in-
ﬂammatory sites, demonstrating that not only cellular but also innate
immunity is impacted by SSRIs [24].
2.1. Proliferation
In the last decades, several research groups have demonstrated that
micromolar concentrations of SSRIs are capable of altering lymphocyteproliferation. In vitro exposure to paroxetine, sertraline and ﬂuoxetine
has been shown to decrease the proliferation of mitogen-stimulated
lymphocytes in a concentration-dependent manner [5,15,16,25–27].
An anti-proliferative effect has also been observed in Jurkat T cells
[28]. Pellegrino andBayer found that in vivo administration ofﬂuoxetine
to rats similarly decreased lymphocyte proliferation when induced by
mitogens ex vivo [29,30]. The effect, however, seems to be dependent
on the activation status of the cells. At suboptimalmitogenic Concanavalin
A (ConA) concentrations, relatively low concentrations (0.1–1 μM) of
ﬂuoxetine have been found to stimulate T cell proliferation [15,18]. In
contrast, at optimal ConA concentrations, 1 μM ﬂuoxetine inhibited T
cell proliferation and a maximal suppressive effect was reached at 10
μM [15]. Although in some situations low levels of ﬂuoxetine seem to
stimulate lymphocyte proliferation, the majority of research in general
points to a negative immunoregulatory effect of SSRIs on lymphocytes.
Our own data support the observation that SSRIs reduce T cell prolifera-
tion in a concentration-dependent manner at concentrations equal to or
higher than 1 μM,when stimulatedwith anti-CD3/CD28 beads [14]. In ad-
dition to ﬂuoxetine, other clinically available SSRIs (paroxetine, sertraline,
citalopram, and ﬂuvoxamine) also appear to induce this anti-proliferative
effect [14]. Although the SSRI concentrations used in in vitro experiments
are in themicromolar range, the anti-proliferative effect is concentration-
dependent, indicating that this effect is speciﬁc and not due to general
toxicity.
2.2. Cytokine secretion
Although investigated the most extensively, proliferation is not the
only parameter affected by SSRIs. The functional ability of lymphocytes,
under the form of cytokine secretion, is equally affected. For example,
20 μM citalopram decreased IL-2 and IFNγ secretion by mitogen-
activated T cells [31]. Furthermore, paroxetine and sertraline (0–30 μM)
have been demonstrated to reduce TNFα secretion by human anti-CD3
stimulated T lymphocytes [5]. Others showed that sertraline (0.01 and
1 μM) signiﬁcantly decreases the IFNγ/IL-10 ratio in the supernatant
of mitogen-stimulated whole blood [7,32]. Although these studies
point in the same direction, showing a suppressive effect of SSRIs on
the production of pro-inﬂammatory cytokines, it should be noted that
these studies are not equal in terms of experimental setup. Whereas
the ﬁrst two studies used puriﬁed lymphocytes, Maes et al. used
whole blood assays. In the latter model interactions between different
types of blood cells are preserved, and this model is therefore believed
to be more representative for the in vivo situation. Recently, Shenoy
et al. demonstrated that not only peripheral blood lymphocyte but
also thymocyte cytokine production is suppressed by citalopram [33].
Concentrations ranging from 25 to 250 μM citalopram completely
suppressed anti-CD3 triggered IL2 production, severely reduced IL4
and partially suppressed IL17 production [33]. As is the case for the
anti-proliferative effect of SSRIs, suppression of cytokine production
is a concentration-dependent effect, conﬁrming that it is not due to
general cytotoxicity.
2.3. Apoptosis
Finally, SSRIs have been shown to induce apoptosis in lymphocytes.
Whereas paroxetine and sertraline were found to decrease activated T
cell viability with an IC50 of around 10 μM [5], other SSRIs exerted this
effect only at tenfold higher concentrations. For citalopram, an IC50 of
180 μM was reported for pro-apoptotic action on naïve T cells [34].
According to our own research, this apoptotic effect is induced by all
SSRIs used in clinical practice (paroxetine, ﬂuoxetine, sertraline,
ﬂuvoxamine and citalopram), albeit in different concentration ranges
[14].
Not only do SSRIs affect the function of healthy lymphocytes, but
they also seem capable of reducing the viability of several cancerous
immune cells. Amit et al. showed that paroxetine (IC50 = 18 μM) and
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Burkitt lymphoma cells, SSRIs (ﬂuoxetine IC50 = 9.3 μM, paroxetine
IC50 = 6.9 μM and citalopram IC50 = 20.9 μM) could induce extensive
apoptosis [22]. Also other cancerous cell lines, such as colon cancer
cells are sensitive to the anti-proliferative and pro-apoptotic actions of
SSRIs [23]. In comparison with cancer cells, resting peripheral lympho-
cytes are much less sensitive to the effects of SSRIs [22]. In contrast,
actively proliferating lymphocytes respond to SSRIs in a comparable
way as cancerous immune cells [35]. Our own data support that there
is a difference in sensitivity to the pro-apoptotic action of SSRIs between
activated and resting T cells, and that activated T cells undergo apoptosis
at signiﬁcantly lower SSRI concentrations [14]. According to Schuster
et al., this discrepancy between resting and activated lymphocytes is
due to the intrinsic higher sensitivity of proliferating cells to undergo ap-
optosis [35]. However, since the exact mechanism by which SSRIs in-
duce their effects has yet to be established, other possibilities
explaining the different responses cannot be excluded. In resting
tonsilar B cells, serotonin transporter (SERT) protein was undetectable
or expressed in only small amounts. Upon activation with mitogens, B
cells upregulated SERT [36]. The observation that proliferating B cells
were more sensitive to SSRI-induced effects than were resting B cells
[36] leads to the assumption that SERT expression is an important factor
in the execution of the immunological effect of SSRIs.
3. Potential mechanisms of action
Although the immunological effects of SSRIs have been described by
several research groups, little is known about the mechanism underly-
ing these effects. Initially, the inhibition of SERT and consequent rise
in extracellular 5HT concentration were thought to be responsible forFig. 1. Possible mechanisms underlying the anti-proliferative and apoptotic effects of SSRIs on l
on 5HT receptors, thereby reducing lymphocyte proliferation. The inability to take up 5HT itse
thereby activating the PKA pathway; SSRIs inhibit translocation of PKC, ultimately resulting in
cell proliferation in response to optimal mitogen concentrations. C) SSRIs induce activation of th
species (ROS), upregulation of Fas and downregulation of bcl-2 and c-myc.the anti-proliferative and pro-apoptotic action of SSRIs on lymphocytes.
More recent research, however, provides several arguments against this
assumption. Other research has focused on the participation of direct
triggering or inhibition of signal transduction pathways in the immuno-
logical effects of SSRIs and on the pathways underlying the apoptotic
action of SSRIs. Finally, some of the current views on antidepressant
action in depression, such as modulation of membrane-associated
lipid rafts or activation of the glucocorticoid receptor, may also be of
importance in the immunomodulatory effects of SSRIs.
3.1. Involvement of 5HT and its transporter
Early work concerning the immunological effects of SSRIs assumed
5HT to be involved in the mechanism underlying the effects of SSRIs
on lymphocytes. It was postulated that SSRIs increased the extracellular
5HT concentration by blockage of 5HT uptake through SERT, which has
been shown to be present on the cell surface of lymphocytes (Fig. 1A)
[26,37]. Pellegrino and Bayer demonstrated that elevation of 5HT levels
through the administration of the 5HT precursor 5-hydroxytryptophan
results in a decreased lymphocyte proliferation [29]. Also, when 5HT
synthesis was inhibited in vivo, SSRIs were no longer capable of
suppressing lymphocyte proliferation [29]. Lesioning of serotonergic
neurons in vivo resulted in the same inability of SSRIs to decrease
lymphocyte proliferation [29]. Thus, if no 5HT was present, SSRIs were
not able to increase the extracellular 5HT concentration and no effect
on proliferation was observed. Also, ﬂuoxetine and sertraline, two
SSRIs with distinct chemical structures but with the same capacity to
block SERT, were found to exert similar anti-proliferative effects on
lymphocytes whereas dopamine and noradrenaline reuptake inhibitors
did not [29]. Theseﬁndings suggest an important role of 5HT in the anti-ymphocytes. A) Inhibition of 5HT uptake through SERT results in increased binding of 5HT
lf might as well cause decreased lymphocyte proliferation. B) SSRIs increase cAMP levels,
reduced lymphocyte proliferation and/or SSRIs increase Ca2+ inﬂux, causing reduced T
e apoptotic cascade, with activation of caspase 3 andMAPK, generation of reactive oxygen
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duce apoptosis in Burkitt lymphoma cells [38], and the pro-apoptotic
action of SSRIs thus might as well be explained through the elevation
of extracellular 5HT levels.
In contrast, 5HT has been identiﬁed as an important factor in the
process of T cell activation [39–42]. Several research groups have
shown that antagonism of 5HT receptors, as well as inhibition of 5HT
synthesis, results in impaired T cell activation and proliferation. Both
5HT-1A [39], 5HT-1B [40,41] and 5HT-7 [41] receptors have been
suggested to be involved in this process. Alternatively, it has been
suggested that not the 5HT receptors, but the uptake of 5HT through
SERT accounts for the mitogenic effect of 5HT [43]. Internalization of
5HT through SERTwould lead to proliferation of the cells. Consequently,
the anti-proliferative effect of SSRIs could be explained by the inhibition
of 5HT uptake. These observations point to a stimulatory effect of 5HT
on the activation and proliferation of lymphocytes. Taken together, the
optimal activation of lymphocytes seems to require certain levels
of 5HT, and both too low and too high concentrations result in sub-
optimal lymphocyte activation, proliferation and viability. The role
of 5HT in immune functioning has been described in more detail
elsewhere [44–46].
On the other hand, several arguments have come up recently
that refute the involvement of 5HT and SERT in the immunosuppressive
effect of SSRIs. First, acetylation of ﬂuvoxamine suppressed the
capability of the compound to inhibit 5HT uptake, but did not impair
the anti-proliferative effect [35]. Nevertheless, acetylation of paroxetine
resulted in an increase of the IC50 from 6.5 μM to 93.3 μM [35] and
thus decreased the ability of paroxetine to suppress proliferation.
Whereas the anti-proliferative effect of paroxetine shifted 15-fold by
acetylation, the afﬁnity for SERT decreased over 1000-fold demonstrat-
ing that both effects are not entirely dependent on each other [35].
However, It should also be noted that isomerization of ﬂuvoxamine
from the trans to the cis form canceled its capability to suppress
in vitro neural cell proliferation, aswell as its ability to block 5HT uptake
[47].
Second, the concentrations needed for the inhibition of 5HT uptake
are in the nanomolar range, while those exerting an anti-proliferative
effect are in the micromolar range [16,35]. Although Ferriere et al.
found speciﬁc binding of 3H-paroxetine in ﬁsh lymphocytes to be in
the nanomolar range (0–10 nM), micromolar concentrations were
needed to substantially inhibit 5HT uptake in these cells [48]. Thus,
the anti-proliferative action of SSRIs in the micromolar range might be
explained by the substantial inhibition of 5HT uptake in this concentra-
tion range, notwithstanding speciﬁc binding of SSRIs to SERT already
occurs in the nanomolar range.
Third, it was put forward that HEK293 cells, which were assumed
not to express SERT, were still sensitive to the effects of SSRIs and thus
these effects could not be mediated by SERT inhibition [35]. To this
end, it should be noted that Chamba et al. found SERT expression in
wild-type HEK293 cells both on mRNA and protein levels [49], suggest-
ing that these cells might yet encounter SSRI-induced effects through
SERT inhibition.
Cloonan et al. pointed out that not all SSRIs induced a pro-apoptotic
effect (citalopram did not induce apoptosis in any of the tested cell
lines), whereas they all do inhibit 5HT uptake through SERT. Further,
the same group also showed that 5HT was not able to prevent the
induction of cell death by SSRIs, and that 5HT itself, amongst other
SERT ligands, could not induce apoptosis in the tested malignant cell
lines [50]. In addition, SSRIs did not induce more extensive cell death
in cells expressing higher levels of SERT [50]. Whereas Pellegrino et al.
reported that in vivo administration of noradrenaline and dopamine
reuptake inhibitors in rats did not affect lymphocyte proliferation,
Diamond et al. found that antidepressants, inhibiting the reuptake of
noradrenalin (reboxetine, desipramine) or not inhibiting the reuptake
of any monoamine (trimipramine), were still capable of inhibiting
in vitro T cell proliferation, as well as TNFα secretion [51].Interestingly, it has been hypothesized that binding of monoamines
on SERT can itself induce signal transduction pathways [38]. Possibly,
binding of SSRIs on SERT induces the same changes in signal transduc-
tion pathways. Furthermore, 5HT uptake has been demonstrated to
inﬂuence signal transduction directly through ‘serotonylation’ of small
GTPases [52]. Thus, SSRIs might affect signal transduction through
restriction of available 5HT for serotonylation.
Recently, a modiﬁed SERT knock-in mouse strain (SERT I172M)was
developed that expresses a modiﬁed SERT protein with normal 5HT
recognition and transport, but with a decreased sensitivity for antide-
pressants, including ﬂuoxetine and citalopram [53]. The pranging
question whether or not SERT is involved in the immunomodulating
effects of SSRIs might be answered using this SERT I172M mouse
model [46].
3.2. Effects on signal transduction pathways
Regardless of the blockage of SERT, further downstreamevents lead-
ing to SSRI-induced decreases in proliferation have been investigated by
studying the interference of SSRIs with signal transduction pathways,
such as the cAMP and phosphoinositol systems. SSRIs have been
demonstrated to interfere with the activation of the cAMP-dependent
protein kinase A (PKA) pathway and the activation of protein kinase C
(PKC), as well as with the inﬂux of Ca2+ (Fig. 1B).
cAMP has been shown to be an important regulator of immune
responses by inhibition of T cell proliferation [54]. Consequently, an in-
crease in cAMP in response to SSRIs could explain the anti-proliferative
action of SSRIs on lymphocytes. At optimal concentrations of ConA, ﬂu-
oxetine induced a rise in intracellular cAMP concentration [15,16].
Citalopram similarly elevated cAMP levels in T cells stimulated with
phytohemagglutinin [31]. However, Kenis et al. did not ﬁnd any
increase in cAMP in peripheral blood mononuclear cells exposed to
0.01–1 μM paroxetine [55]. The same group further examined the in-
volvement of cAMP and PKA activation in the immunoregulatory effect
of ﬂuoxetine and concluded that the cAMP-dependent PKA pathway
was probably not involved in the ﬂuoxetine-induced suppression of
the IFNγ/IL-10 ratio, but the activation of PKA might contribute to the
reduction in TNFα secretion [56].
On the other hand, PKC activation stimulates lymphocyte prolifera-
tion [16] and SSRI-mediated suppression of PKC translocation to the
cell surface may account for the anti-proliferative effect. Translocation
of PKC was inhibited by ﬂuoxetine at optimal mitogenic concentrations
[16], which might contribute to the observed anti-proliferative effect.
Further, cytosolic Ca2+ inﬂux is an important factor in lymphocyte
activation and subsequent proliferation [57]. Thus, SSRIsmight interfere
with lymphocyte proliferation through interference with Ca2+ inﬂux.
Edgar et al. demonstrated that ﬂuoxetine exerted similar effects on
mitogen-induced T cell proliferation as calcium ionophores [15]. At
sub-optimal mitogen concentrations, both ﬂuoxetine and calcium
ionophores stimulated T cell proliferation, whereas at optimal mitogen
concentrations, both compounds inhibited T cell proliferation [15].
Thus, when suboptimal mitogen concentrations are used, ﬂuoxetine
might induce an inﬂux of extracellular Ca2+ that enhances T cell prolif-
eration. In T cells exposed to optimal mitogen concentrations, however,
ﬂuoxetine causes an excessively high Ca2+ concentration resulting in
impaired proliferation [15].
In conclusion, interference with the cAMP and phosphoinositol
systems can explain some of the effects of SSRIs on lymphocytes, but
the exact mechanism behind the immunomodulating effects of SSRIs
remains unresolved and therefore requires further investigation.
3.3. Induction of the apoptotic cascade
SSRIs have been found to induce apoptosis in lymphocytes and
cancer cells. The pathways involved in this apoptotic effect have been
investigated extensively. Xia et al. showed that the decrease in cellular
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extensive DNA fragmentation [34]. In lymphocytes exposed to
citalopram, the anti-apoptotic genes c-myc and bcl-2 were downregu-
lated and Fas membrane expression was increased [58]. In cancer
cells, the process involves caspase-3 activation, as was demonstrated
in both Jurkat cells [28] and acute myeloid leukemia HL-60 cells [59].
Early in the apoptotic cascade triggered by SSRIs in HL-60 cells, reactive
oxygen species are formed, and this precedes the change in mitochon-
drial trans-membrane potential [60]. Further, Taler et al. showed an
activation of the MAPK death signaling pathway and suppression of
the anti-apoptotic protein bcl-2 in mitogen-activated rat splenocytes
[27]. In conclusion, several well-knownmechanisms leading to apopto-
sis are involved in the process bywhich SSRIs reduce cellular viability of
lymphocytes (Fig. 1C).3.4. Unexplored mechanisms
In addition to the abovementioned targets that have been investi-
gated in lymphocytes to a greater or lesser extent, other mechanisms
explaining the antidepressive action of SSRIs might as well account for
their immunological effects. Amongst others, it was suggested that
SSRIs might directly inﬂuence mitochondrial pathways, as was demon-
strated for clomipramine in human glioma cells [61,62]. Furthermore, it
was proposed that SSRIs could affect cell dynamics through e.g. phos-
pholipid binding and lysosomal trapping, given their lipophilic and
amphiphilic nature [61]. In this respect, SSRIs have been found to accu-
mulate in membrane-associated lipid rafts in HEK293 and N1E-115
neuroblastoma cells [63]. Moreover, antidepressants have been shown
to enhance G protein Sαmigration from lipid rafts and thereby facilitate
adenylyl cyclase activity and cAMP formation in C6 glioma cells [64]. As
a result, signal transduction post G protein-coupled receptor activation
is enhanced. The observed rise in cAMP after SSRI treatment of T lym-
phocytes activated with mitogens as described by Edgar et al. [15,16]
and Xia et al. [31] might relate to the effects of SSRIs on lipid rafts.
Given the presumed importance of lipid rafts in TCR clustering during
T cell activation [65], SSRIs might disturb T cell function either directly
via disturbance of lipid raft integrity or indirectly via enhanced G
protein signaling.
Another possible mechanism is the upregulation of the glucocorti-
coid receptor (GR). Antidepressants have been shown to increase GR
expression, promote GR nuclear translocation and enhance GR function
in mouse ﬁbroblasts [66,67]. As glucocorticoids have strong immuno-
suppressive effects, it is possible that SSRIs exert their immunosuppres-
sive effects on T lymphocytes through GR modulation. However, these
suggestions have not been investigated in lymphocytes and further
research will be necessary to clarify whether the immunomodulatingTable 1
Animal studies of SSRIs in autoimmune diseases and graft-versus-host disease.
SSRI Pathology Animal model/speci
Paroxetine Multiple sclerosis EAE, murine
Fluoxetine Allergic asthma Ovalbumin-sensitiza
Septic shock LPS-induced, murine
Inﬂammatory bowel disease Acetic acid, rat
Rheumatoid arthritis CIA, murine
Inﬂammatory bowel disease DSS, murine
Multiple sclerosis EAE, rat
Contact hypersensitivity Picryl chloride, muri
Graft-versus-host disease Bone marrow transp
Sertraline Multiple sclerosis EAE, murine
Rheumatoid arthritis CIA, rat
Citalopram Rheumatoid arthritis CIA, murine
Venlafaxine Multiple sclerosis EAE, murineeffects of SSRIs are mediated through any of the abovementioned
mechanisms.
4. Animal studies of SSRIs as immunosuppressants
As it became more and more clear that SSRIs induced signiﬁcant
changes in immune cells, the possibility to use SSRIs in immune related
pathologies was investigated. Two distinct possibilities have already
been described: ﬁrst, SSRIs were suggested as drugs to suppress
unwanted immune responses in autoimmune diseases. Second, SSRIs
were proposed as immunosuppressants to inhibit allogeneic T cell
responses after transplantation. An overview is given in Table 1.
4.1. Autoimmune diseases
The potentially beneﬁcial effects of SSRIs in autoimmune diseases
have been tested in animal models of multiple sclerosis, rheumatoid
arthritis, contact hypersensitivity reaction, inﬂammatory bowel dis-
eases, septic shock and allergic asthma. In experimental autoimmune
encephalomyelitis (EAE), a murine model of multiple sclerosis (MS),
venlafaxine, paroxetine and sertralinewere tested and both venlafaxine
and sertraline were able to ameliorate the clinical symptoms of the
disease (tail limpness, paraparesis, and hindlimb and forelimb paralysis)
[13,68]. Paroxetine did not affect the clinical progression of EAE [13].
However, animals were treated with only 5 mg/kg paroxetine, which
may have failed to induce high enough plasma concentrations to reach
an immunomodulatory effect. Cytokine secretion was also investigated
and sertraline decreased the secretion of IFNγ, TNFα and IL-2 as well as
the viability and in vitro proliferation of EAE splenocytes [13]. Histological
examination of venlafaxine-treated animals revealed decreased central
nerve system inﬂammation and inﬁltration of inﬂammatory cells in the
brain and spinal cord [68]. Venlafaxine also reduced pro-inﬂammatory
cytokine secretion (IL12 p40, IFNγ, and TNFα) and diminished mRNA
expression of inﬂammatory genes [68]. In a similar multiple sclerosis
model in rats, ﬂuoxetine has recently been shown to promote remission
of EAE [69]. Fluoxetine-pretreated rats recovered faster and clinical scores
during remissionwere lower than those found in vehicle-treated animals
[69]. Spinal cord demyelination and inﬂammatory foci were reduced and
IFNγ production was suppressed [69].
In a murine model for rheumatoid arthritis (RA), ﬂuoxetine and
citalopram were tested and both SSRIs were able to reduce clinical
scores (based on the occurrence of erythema, swelling and joint
deformity with ankylosis) [12]. Fluoxetine additionally improved paw
thickness and signiﬁcantly reduced IL12 secretion, whereas citalopram
did not [12]. Histological examination of the affected joints revealed re-
duced inﬂammation, cartilage and bone erosion in ﬂuoxetine-treatedes Beneﬁcial effect Reference(s)
No Taler et al. [13]
tion, rat Yes Roumestan et al. [11]
Yes Roumestan et al. [11]
Yes Guemei et al. [70]
Yes Sacre et al. [12]
Yes Koh et al. [9]
Yes Yuan et al. [69]
ne Yes Kubera et al. [10]
lantation, murine Yes Gobin et al. [14]
Yes, moderately Taler et al. [13]
Yes Baharav et al. [8]
Yes, partial Sacre et al. [12]
Yes Vollmar, et al [85]
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pannus formation and joint deformation in citalopram-treated mice
[12]. Further, a beneﬁcial effect of sertraline has been demonstrated in
a rat model of RA [8]. The decrease in clinical symptoms was accompa-
nied by an increase in IL10 secretion, and a decrease in TNFα and cox2
levels [8].
Recently, the effect of ﬂuoxetine on murine contact hypersensitivity
(CS) reaction of the skin has been studied [10]. CS is a T cell mediated
immune reaction that was successfully suppressed by ﬂuoxetine as
determined by the reduction in swelling of the ear to which the contact
allergenwas applied. Theweight of axillary lymphnodeswas decreased
and the production of IL10, an anti-inﬂammatory cytokine, was
increased by ﬂuoxetine [10].
Inﬂammatory bowel disease is another example of an immunologi-
cal disorder that might beneﬁt from SSRI treatment. This disease is
caused by a dysregulation of the gastro-intestinal immune system and
is considered to be the result of an altered immune response to luminal
antigens. In a dextran sulfate sodium (DSS)-induced murine model
for colitis, ﬂuoxetine showed to improve the disease activity index,
consisting of a composite score for weight loss, stool consistency and
gross rectal bleeding [9]. Histological examination of the proximal and
distal colon showed less inﬁltration of inﬂammatory cells and reduced
impairment of the glandular architecture in ﬂuoxetine-treated animals
versus controls. Another study demonstrated that ﬂuoxetine and desip-
ramine attenuate acetic acid-induced experimental colitis in rats [70]. In
addition to a reduction of colonic damage, ﬂuoxetine and desipramine
suppressed serum cytokine levels (TNFα, IL1β) that were induced by
experimental colitis [70].
Finally, in a lipopolysaccharide-induced murine model of septic
shock, preventive administration of ﬂuoxetine diminished the expres-
sion of TNFα and the mortality rate [11]. In a rat model of allergic
asthma, ﬂuoxetine reduced lung inﬂammation and inﬁltration of
inﬂammatory cell types [11]. Fluoxetine reduced not only the number
of lymphocytes, but also the number of macrophages, neutrophils and
eosinophils [11]. In vitro, ﬂuoxetine dose-dependently inhibited the
release of TNF-α from LPS-treated monocytes [11].
The abovementioned studies demonstrate the potential use of SSRIs
in awide variety of autoimmunediseases. Nonetheless, thedata are lim-
ited and further research is needed to evaluate which SSRI, which dose
and which dosage regimen are optimal for each individual pathology.
To date, most preclinical evidence of immunosuppression exists for ﬂu-
oxetine (Table 1). Whereas ﬂuoxetine is deﬁnitely a suitable candidate
to proceed to clinical testing, it is worthwhile to screen the effect of
other SSRIs in autoimmune disorders as well, as these might show to
be equally or even more effective. Other autoimmune disorders, such
as diabetes mellitus type 1, lupus erythematosus, autoimmune thyroid
diseases and others might as well beneﬁt from SSRI treatment and
studies exploring the potential use of SSRIs in these disorders should
be encouraged.
4.2. Graft-versus-host disease
Unwanted immune activation not only occurs in autoimmune disor-
ders, but also in transplantation. For instance, alloreactive T cells present
in the graft can cause graft-versus-host disease (GvHD) after hemato-
poietic stem cell transplantation. As in autoimmune diseases, the possi-
bility to prevent or suppress this major complication with SSRIs has
been investigated. Fluoxetine (20 mg/kg) was able to reduce clinical
symptoms of acute GvHD in a MHC-matched, minor histocompatibility
mismatched bone marrow transplantation model [14]. In comparison
with vehicle-treated controls, ﬂuoxetine reduced the occurrence of
rufﬂed fur, hunched posture, lethargy, diarrhea, weight loss and inﬂam-
mation of the eyes after transplantation of T cell-enriched bonemarrow
in lethally irradiatedmice. In addition,ﬂuoxetine increased the percent-
age survival of mice six months after transplantation in comparison to
controls. In the peripheral blood of ﬂuoxetine-treated mice, asigniﬁcantly lower percentage of alloreactive T cells could be detected,
demonstrating that ﬂuoxetine was able to reduce alloreactive T cell
proliferation, and/or increase apoptosis of these cells [14]. Although
concern has been raised that SSRIs might elevate prolactin levels and
thereby negatively inﬂuence graft fate [71], ﬂuoxetine appears to have
an overall beneﬁcial effect on GvHD without affecting the efﬁciency of
the stem cell transplantation [14].
Whereas corticosteroids form the golden standard therapy for acute
GvHD, these drugs can induce severe side effects such as increased in-
fection risk, Cushing syndrome, diabetes, osteoporosis and myopathy
[72]. In comparison, SSRIs have a more beneﬁcial side effect proﬁle
with nausea, diarrhea, sexual dysfunction, headache, dizziness,
agitation and insomnia [3]. Furthermore, steroid treatment results in
complete remission in less than half of the patients [73], indicating
that new treatment options are highly necessary.
In the past decades, it has become more and more clear that hema-
topoietic stem cell transplantation is a successful therapy for leukemia
not only because of the replacement of the blood forming compartment,
but also because of the anti-leukemia effect that is executed by the graft
[74]. However, GvHD and graft-versus-leukemia effect often go hand-
in-hand and are at least in part mediated by the same effector cells
and target antigens [74]. Whereas ﬂuoxetine has been shown to sup-
press GvHD, the impact of this drug on graft-versus-leukemia effect
has not been investigated. Therefore, further research will be necessary
to evaluate whether the anti-leukemia effect is maintained during SSRI
therapy.
5. From bench to bedside
Although the beneﬁcial effects of SSRIs in divergent autoimmune
diseases and cancer were demonstrated by several research groups,
discussion remains on whether SSRIs are suitable candidates for
immunomodulation in the clinic. The main concern relates to the plas-
ma concentrations that are believed to be necessary in order to achieve
an immunosuppressive effect with SSRIs. Although these concerns are
valid, limited evidence is already available that SSRIs have a beneﬁcial
effect in MS and RA patients [75,76].
5.1. Plasma concentrations
There is a considerable difference between the SSRI concentrations
that are reported to exert immunosuppressive effects in vitro, and the
ones found in plasma of depressed patients. Concentrations used
in vitro for immunosuppressive effects range from 1 to 20 μM for parox-
etine, ﬂuoxetine and sertraline and even higher for the other SSRIs.
These concentrations are considerably higher than plasma concentra-
tions found in depressed patients, which range from 10 to 600 ng/ml
or 0.03 to 1.6 μM [77,78].
However, various factors contribute to the reasoning that SSRIs
might still be suitable for immunomodulation in vivo. First, SSRI concen-
trationsmight vary considerably between organs and lymphocytesmay
be exposed to high enough SSRI concentrations in peripheral compart-
ments instead of in the blood. Uhr et al. determined plasma and organ
concentrations of SSRIs after subcutaneous injection in mice and
found 10-fold higher concentrations in spleen compared to plasma
[79]. Thus, lymphocytes might be exposed to SSRI-concentrations high
enough for immunomodulation in the spleen while plasma concentra-
tions can be kept low.
Second, evidence exists that doses currently used in patients already
exert immunomodulatory effects. For instance, Reed and Glick reported
reactivation of herpes simplex virus in patients receiving high doses of
SSRIs [6]. A case of recurring sinusitis was reported in a patient suffering
from obsessive–compulsive disorder and treated with high doses of
venlafaxine [80]. Thus, the concentrationsneeded to obtain an immuno-
suppressive effect in vitro might not correlate with those exerting an
immunosuppressive effect in vivo.
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animal experiments give rise to plasma concentrations within the same
range as concentrations found in patients. Chronic daily administration
of 10 to 18 mg/kg ﬂuoxetine orally given to mice gives rise to plasma
concentrations within the same range as those found in patients
(100–700 ng/ml) [81]. Several of the animal experiments analyzing
the effect of ﬂuoxetine on autoimmune disease and cancer used
doses below 20 mg/kg/day and reported signiﬁcant changes in immune
function and symptoms [12,17,18]. Others reported doses below
20 mg/kg/day to already exert small changes in immune function, but
higher doses were needed in order to reach signiﬁcance [12].
Finally, if higher dosing would be necessary, this may be achieved
without severe adverse effects. Barbey and Roose concluded from a
comprehensive literature search that SSRI doses up to thirty times the
normal daily dose do not induce any side effects or only minor effects.
Only at doses exceeding 75 times the normal daily doses, more severe
adverse effects occurred [82]. Doses two to three times higher than
the ones used for the treatment of depression are already being sub-
scribed for other disorders, such as obsessive compulsive disorder
without unacceptable side effects [83]. Although to our knowledge, no
data are available on plasma concentrations in OCD patients, one
might expect these to be much higher, given the non-linear kinetics of
most SSRIs. This was conﬁrmed for ﬂuoxetine in mice, where a chronic
dose of 25 mg/kg per day gave rise to a plasma concentration 3.15 times
higher than the plasma concentration obtained after a chronic dose of
18 mg/kg (the latter dose gives rise to a plasma concentration within
the same range as those found in patients) [81].
Nevertheless, one aspect that needs further attention is the poten-
tially increased risk to commit suicide under treatment with SSRIs.
There is limited evidence that antidepressant treatment might elevate
the risk of suicide in depressed patients, especially at the start of
treatment [2]. When using SSRIs as immunosuppressants in patients
suffering from autoimmune disorders or GvHD, in particular when con-
comitant depression is present, the potentially increased risk of suicide
should be considered. In undepressed patients, this seems less to be an
issue, as the increased suicide risk with antidepressants is associated
with the underlying depression [2].
Thus, although immunoregulatory application of SSRIs will probably
require higher doses than the ones currently used for the treatment of
major depressive disorder, there are indications that achieving the
needed plasma concentrations may be feasible without competing
against unacceptable side effects.5.2. Clinical evidence supporting the human use of SSRIs
as immunosuppressants
Although clinical evidence for SSRI use in autoimmune diseases is
scarce, two studies have been conducted that demonstrate the useful-
ness of SSRIs in MS and RA. In undepressed patients with relapsing
MS, ﬂuoxetine (20 mg/day) reduced the occurrence of new enhancing
lesions, as measured by an MRI scan [75]. The beneﬁcial effect was
attributed to an anti-inﬂammatory effect of ﬂuoxetine on astrocytes,
rather than a suppressive effect on peripheral lymphocytes. The periph-
eral effects on immune cells, however, were not investigated.
In RA patients, a clinical trial was performed to evaluate the efﬁcacy
of paroxetine and amitriptyline for concurrent depression [76]. In addi-
tion to an improvement in depressive symptomatology, an improve-
ment of RA associated pain and disability has also been detected with
both paroxetine (20–40 mg/day) and amitriptyline (75–150 mg/day).
Although this study did not measure direct immunological parameters,
the improvement in RA symptoms seems to indicate a beneﬁcial effect
of paroxetine and amitriptyline in this pathology. It is not clear, however,
whether this is a direct effect of the antidepressants on immune
parameters, or an indirect effect through resolving the depressive
symptomatology which is known to exacerbate the arthritic symptoms[76]. In order to differentiate between both possibilities, studies in non-
depressed RA patients should be conducted.
Furthermore, a patient suffering from RA was found to be in remis-
sion when treated with citalopram for concurrent depression and dis-
continuation of citalopram treatment resulted in reoccurrence of the
rheumatic symptoms [84]. Although it can be argued that the mental
state of a patient inﬂuences his perception of rheumatic symptoms,
this case report mentions a signiﬁcant improvement of DAS 28 score,
which is an objective measure of disease severity. Therefore, it seems
to indicate that there is a direct link between SSRI treatment and sever-
ity of RA symptoms in this patient.
This limited evidence is encouraging for the use of SSRIs in autoim-
mune disorders, even with doses in the same range as the ones used
for the treatment of depression. However, more extensive studies are
needed to evaluate the immunosuppressive potential of SSRIs and the
doses needed to achieve an optimal effect in each individual pathology.
6. Conclusion
SSRIs clearly exert immunological effects that potentially could be
used to alter immune responses in autoimmune pathologies and graft-
versus-host disease. Whereas the impact of SSRIs on proliferation,
cytokine secretion and apoptosis of lymphocytes has already been
well characterized, the underlyingmechanism still needs further inves-
tigation. Although discussion remains about whether or not SSRIs can
be administered in high enough doses to exert the immunosuppressive
effects, they are an interesting new treatment option and further
research in the area should be encouraged.
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